The Influence of Bisphenol A on adults Humour and Anxiety by Barbara Joana Gouveia Lopes de Almeida
2013/2014 
Bárbara Joana Gouveia Lopes de Almeida   
The Influence of  Bisphenol A on 
adults Humour and Anxiety 
março, 2014 
Mestrado Integrado em Medicina 
 
Área: Neurociências Clínicas e Saúde Mental 
 
Trabalho efetuado sob a Orientação de: 
Professor Doutor Rui Coelho 
E sob a Coorientação de: 
Professora Conceição Calhau  
 
Trabalho organizado de acordo com as normas da revista: 
The International Journal of Clinical Neurosciences and 
Mental Health 
Bárbara Joana Gouveia Lopes de Almeida 
The Influence of Bisphenol A on 
adults Humour and Anxiety 
março, 2014 


  
 
 
 
 
 
 
 
To my parents  
and to my lovely sister.  
Title: The Influence of Bisphenol A on Adults Humour and Anxiety 
 
Author:  
Almeida Ba, Sá Cb, Sá Lc,d, Faria A PhDb,d,e, Teixeira Db, Calhau C PhDb,f, Domingues V 
PhDc, Coelho R MD PhDg 
 
Author information:  
aFaculty of Medicine, University of Porto, Porto, Portugal 
bDepartment of Biochemistry (U38-FCT), Faculty of Medicine, University of Porto, 
Porto, Portugal 
cRequimte, Instituto Superior de Engenharia, Instituto Politécnico do Porto, Porto, 
Portugal 
dFaculty Nutrition and Food Sciences, University of Porto, Porto, Portugal 
eChemistry Investigation Centre (CIQ), Department of Chemistry, Faculty of Sciences, 
University of Porto, Porto, Portugal 
fCINTESIS Center for Research in Health Technologies and Information Systems, 
Faculty of Medicine, Porto University, Porto, Portugal 
gDepartment of Clinical Neurosciences and Mental Health, Hospital de São João, 
Faculty of Medicine, University of Porto, Porto, Portugal 
 
Corresponding author: Conceição Calhau. 
Department of Biochemistry, CIM, Centro de Investigação Médica 
Faculty of Medicine of University of Porto 
Alameda Prof. Hernâni Monteiro 
4200-319 Porto 
Portugal. 
 
Keywords: Anxiety; Bisphenol A; Depression; Endocrine Disruptors.  
 
A running head: BPA and psychoparameters  
 
Abstract word count: 226 
 
Body text word count: 2 302 
 
Number of tables: 6 
 
The Influence of Bisphenol A on Adults Humour and Anxiety. 1 
 2 
Abstract:  3 
Background/Objective: Bisphenol A (BPA) is one of the most common environmental 4 
endocrine disrupter, present ubiquitously in our daily life. Several animal and human 5 
studies conclude that there is an association between BPA exposure on early 6 
neurodevelopment ages and behavioral alterations, but to date, only few animal studies 7 
had study the influence of BPA on a mature neurodevelopment brain. Also, it has been 8 
proposed that gender interferes with this association. With our study, we aim to 9 
investigate the relation between BPA levels on adulthood and several 10 
psychoparameters. 11 
Material and Methods: Urinary BPA concentration and psychoparameters were 12 
evaluated in a cohort of 30 young adults. A gender-dependent association was also 13 
analyzed. The outcomes measured were based on the Positive and Negative Affect 14 
Schedule (PANAS), Hospital Anxiety and Depression Scale (HADS) and Perceived 15 
Stress Scale (PSS) scores, translated and validated for the portuguese population.   16 
Results: Urinary BPA was detected in 24 individuals, with a mean of 0.34ug/L. BPA 17 
concentration was significantly associated with lower levels of negative affects (B= -18 
9.54; p-value = 0.038). Also, a negative association was found with anxiety (B= -3.65; 19 
p-value=0.108) and depressive (B= -2.41; p-value=0.193) indicators. A positive 20 
association was shown with higher levels on PSS (B= 4.12; p-value= 0.360). No 21 
gender influence was established in the main analyses.  22 
Conclusions: These results suggest that BPA can influence behavioral parameters in a 23 
young adult population. 24 
 25 
Body Text: 26 
Introduction: 27 
Bisphenol A (BPA) is one of the most common environmental endocrine disrupter, with 28 
a production of > 8 billion pounds each year and>100 tons released into the 29 
atmosphere yearly (1). 30 
BPA is a monomer used in the manufacture of polycarbonate plastics and epoxy resins, 31 
found extensively in our daily life including baby bottles, reusable water bottles, 32 
reusable food containers, papers, toys, water pipes, drinking containers, eyeglass 33 
lenses, sports safety equipment, dental monomers, medical equipment and tubing, and 34 
consumer electronics. BPA has been shown to leach from food and beverage 35 
containers, and some dental sealants and composites under normal conditions of use 36 
(2, 3). In according to several studies, in humans, BPA can be detected in serum, urine, 37 
amniotic fluid, follicular fluid, placental tissue, and umbilical cord blood (2). Ingestion is 38 
considered the major route of BPA exposure in humans, although transdermal 39 
exposure and inhalation are also possible routes. Indeed, there are works pointing out 40 
that BPA was detected in 99 % and 92.6 % of urine samples from German (4) and from 41 
US general population (5) , respectively. 42 
Several studies have been conducted to evaluate the impact of BPA on human health. 43 
Lang et al. found a positive association between urinary BPA levels and diabetes, heart 44 
disease and liver toxicity (6); other associations that have been detected are with: 45 
obesity, endometrial hyperplasia, endometriosis and PCOD, chromosomal 46 
abnormalities and recurrent miscarriage (2).   47 
In addition to the issues referred, other major concern about BPA levels and human 48 
health is its impact on neurobehavioral. Several animal studies conclude that there is 49 
an association between BPA exposure and behavioral alterations, namely anxiety and 50 
depression-like behavior. However these results are contradictory in relation to gender 51 
dependence/ independence association, increase/ decrease in anxiety and depression 52 
and the time of exposure (7-14). Most studies have been realized in rodents with 53 
prenatal or perinatal exposure and only few have been taken in account the exposure 54 
in young adulthood, a time when also important neuronal alteration can take place (15-55 
17). 56 
To date, only few human studies have been realized, all of them in children with less 57 
than 11 years of age and also with contradictory conclusions (18-22).  58 
There is a lack of data about this compound exposure in adulthood and 59 
neurobehavioral dysfunctions. To address more information to this issue, in the present 60 
work, we aim to study the putative association between the levels of urinary BPA and 61 
anxious and depressive symptoms in a population of 30 young adults. Since BPA is an 62 
endocrine disruptor, the study was realized in a male and in a female sample. 63 
 64 
Methods: 65 
Selection of the individuals: The Ethics Committee of Centro Hospitalar São João, EPE 66 
- Hospital de São João/Faculty of Medicine of the Porto University and informed 67 
consent was obtained from all study participants. The individuals of this study were 68 
volunteers that respond to an advertisement published in the student community of the 69 
Faculty of Medicine of Porto University. Inclusion criteria were: age between 20 and 23 70 
years old and attending clinical practice. From the volunteers 15 male students and 15 71 
female students were randomly selected.  72 
Data Source: demographical and psychometric data were collected from self-report 73 
inventories that individuals responded in a controlled environment. The scales used 74 
were the Perceived Stress Scale, the Hospital Anxiety and Depression Scale and the 75 
Positive and Negative Affect Schedule, all of them translated and validated for the 76 
portuguese population (23-25). 77 
Perceived Stress Scale measures the degree to which respondents perceive their lives 78 
to be stressful, uncontrollable, unpredictable, and overloaded during the previous 79 
month.  The PSS consists of 10 items using five-point scales, each ranging from 0 80 
(never) to 4 (very often). Half the items are reverse coded, and all the scores are then 81 
summed to obtain a total score (26). 82 
Hospital Anxiety and Depression Scale records levels of depression and anxiety 83 
symptoms. HADS consists in 14 statements, 7 related to anxiety symptoms and 7 84 
related to depression levels, score on a four-point scale. The sum score of each 85 
subscale (levels anxiety and depression symptoms) ranges from 0 to 21 (27). 86 
Positive and negative affect:  This scale instructs participants to rate to what extent 87 
they generally have experienced 20 different feelings or emotions (10 positive affects 88 
and 10 negative affects) during the previous weeks, from 1 (very slightly) to 5 89 
(extremely) (28). 90 
Urinary BPA Concentrations: 91 
The volunteers were asked to collect the first urine of the morning, to a proper 92 
recipient, being advised not to practice vigorous exercise the day before. The urines 93 
were collected in the same day and stored at -20ºC until analysis. Later, total urinary 94 
BPA concentrations were measured according to the procedure described by Mansilha 95 
et al. (29), using a solid phase extraction combined with liquid chromatography tandem 96 
mass spectrometry. The urine samples were incubated with E. coli beta-glucuronidase 97 
to obtain the free and the conjugated forms. The chromatographic analyses were 98 
carried out in a Thermo Trace-Ultra Gas Chromatograph coupled to an Ion trap mass 99 
detector thermo polaris. The limit of detection (LOD) was 0.0019 µg/L and the Limit of 100 
Quantification was 0.0062 µg/L. The method accuracy was 68%. The BPA levels were 101 
normalized with urinary creatinine concentrations.  102 
Covariates: 103 
Covariates were selected based on whether they were known or suspected risk factors 104 
according to the literature. We included the following potential confounding variables: 105 
social-economic status, chronic disease, medications, smoking and alcohol 106 
consumption. Since all the individuals were medical students and none was doing any 107 
pharmacological treatment, we did not consider education and medication as 108 
confounders. 109 
Statistical Analysis: 110 
Descriptive statistics was used to analyze social-demographic factors. To control urine 111 
dilution BPA concentration was divided by urinary creatinine to obtain normalized 112 
values. The scales outcomes and the BPA-creatinine-standardized-concentrations 113 
followed a normal distribution and were examined as continuous variables. Individual 114 
differences in respect to the psychometric scores and BPA concentrations were 115 
estimated using Student's t-tests.  We performed multiple linear regression analyses 116 
using urinary BPA as the independent variable, and adjusting for various confounders: 117 
gender, socioeconomic status, smoking and alcohol habits. Next, we did the same 118 
analyzes but comparing results by gender. All statistical analyses were performed 119 
using IBM® SPSS Statistics, version 21.0. All results were considered statically 120 
significant when p-value was less than 0.05. 121 
 122 
Results: 123 
A total of 30 individuals participated in the study. Six were excluded: two didn't have 124 
detectable levels of urinary BPA (LOD < 0.0019 µg/L); three had detectable levels, but 125 
they were too high for the calibration curve used. The last individual was excluded 126 
because he had outliers scores in the PSS and in the negative PANAS scales. No 127 
other parameters invalidated the participation of the volunteers. The mean age was 23 128 
years old (range 22-24); 12 were female and 12 were male (50.00%). All were single 129 
and higher educated; no one suffered from psychiatric disorders or was taking 130 
medication (See Table 1). 131 
Urinary BPA concentration was standardized with creatinine level, to diminish the error 132 
associated with urine dilution. The levels ranged from 0.04 µg/L to 1.35 µg/L, with a 133 
mean of 0.34 µg/L (SD 0.33). The difference between female and male urinary BPA-134 
creatinine-standardized levels was not statically significant (table 2). The scales were 135 
normally distributed; Table 3 shows the mean and the standard deviation for each 136 
scale: the Positive PANAS scale had a mean score of 33.38, with a minimum value of 137 
25 and maximum of 45. The mean negative PANAS was 22.04, ranging from 11 to 34; 138 
The HADS anxiety subscale had values between 3 and 15, with a mean of 7.71. 139 
Depression subscale had lower levels: mean of 3.50, extending from 0 to 9. The PSS 140 
showed the values between 10 to 34, being the mean 22.58. None of the scales 141 
presented significant differences among females and males. The Pearson correlation 142 
between the scales is presented in table 4: although they evaluate different 143 
parameters, they are related to each other. The associations between urinary BPA and 144 
the psychoparameters evaluated, are showed in table 5. After correction for the co-145 
varieties, the analyses revealed: a negative association statically significant was found 146 
between urinary BPA and negative PANAS scores (Beta unstandardized= -9.54; R2= 147 
0.29; p-value = 0.038). BPA is also negatively associated with anxiety (Beta 148 
unstandardized= -3.65; R2= 0.24; p-value=0.108) and depression (Beta 149 
unstandardized= -2.41; R2=0.11; p-value=0.193) on HADS. A positive association was 150 
found with higher levels on PSS (Beta unstandardized= 4.12; R2=0.14; p-value= 151 
0.360). Although the beta unstandardized calculated for the gender is very low, taking 152 
into account the literature and the fact that our sample is small and can therefore 153 
dissipate some interactions, we did a separate analyses for females and males. Table 6 154 
presents the results by sex: Positive PANAS score have different values on females 155 
and males: in the first, BPA is positively associated with positive affects (Beta 156 
unstandardized= 8.91; R2=0.25; p-value=0.283) while the opposite happens in males 157 
(Beta unstandardized= 6.73; R2=0.34; p-value=0.181). The others parameters show 158 
equal interactions although females have stronger associations in the negative affects 159 
(R square=0.44 in females versus R square= 0.22 in males) and depression levels (R 160 
square=0.39 versus R square= 0.23). The anxiety parameter and the perceived stress 161 
have the same level of association in both genders (R square= 0.33 for females, and R 162 
square=0.35; R square= 0.31 for females, and R square=0.38, respectively). 163 
 164 
Discussion: 165 
Bisphenol A is increasing its importance because of its adverse effects in various 166 
systems, namely in Central Nervous System with consequent neurobehavioral 167 
disruptions. Nevertheless, the majority of the studies in this area are: 1) with animal 168 
models and 2) the human studies, focus their attention in early development stages, 169 
namely on pre-natal, postnatal and childhood exposure. Our study is pioneer since it is 170 
the first that establish a relation between neurobehavioral alterations and BPA 171 
exposure in adulthood on humans. Currently, increasing evidence points to alterations 172 
in various psychometric parameters, although the data are controversial: some studies 173 
point to an anxiogenic effect, others to a null or even anxiolytic action; the same 174 
incongruence also persists in relation to depression levels and other parameters (not 175 
discuss in this article). In our study, we concluded that BPA is associated with an 176 
anxiogenic effect (lower scores in the subscale anxiety of HADS) and with inferior 177 
levels of depressive symptoms and negative affects (measured with the subscale 178 
depression of HADS and with the PANAS). However, BPA was positively associated 179 
with higher levels of perceived stress. Our findings are in agreement with the data 180 
presented by Farabollini et al. (13) and Perera et al. (21), but in disagreement with 181 
others, such as Hong et al. (22) that reported a positive association not only with 182 
anxiety but also with depression scores. Some attention must be taken when 183 
interpreting this evidence: the concentrations of BPA depends on the exposure, for 184 
example through food and beverage containers, dental products, coating of CDs, 185 
DVDs, electronic equipment, automobiles and sports equipment, among others 186 
materials. Thus, high levels of BPA could be associated with life styles that in the short 187 
term can result in wellness (and therefore inferior levels of anxiety and depressive 188 
symptoms and negative affects) but, with prolonged exposure, may lead to harmful 189 
effects, evidenced later in life. Other issue in debate is the possibility of different 190 
responses to BPA between female and male individuals. Although our results didn’t 191 
achieve a p-value < 0.05, a stronger association was observed in females in relation to 192 
negative and depressive scores. Once again, regarding this point, data is inconclusive 193 
both in animal and in human studies. To refer some: Braun et al. (18) as Hong et al. 194 
(22) reported null gender interaction whereas Perera et al. (21) and Harley et al. (20) 195 
conclude that boys and girls have different responses to BPA. This response may 196 
depend on several factors, namely dose, routes and age of exposure, as is evidenced 197 
by Braun et al. (18) and Perera et al. (21), that reported alterations in child behavior 198 
with prenatal but not with childhood exposure. Several studies present possible 199 
mechanisms underlying the disruptions induce by BPA on early neurodevelopment: 200 
alterations in neocortical and spatiotemporal gene expressions (30); disruptions in both 201 
dendritic and synaptic development (31); interference with estrogenic, androgen and 202 
thyroid signaling (32); changes in the dopaminergic system (33). However, there is lack 203 
of information about the influence of this endocrine disruptor on a mature central 204 
nervous system, such as the individuals of our study. Luo et al. (15) attempted to 205 
elucidate this point: they reported that mice exposed during puberty to BPA had 206 
significant lower levels of AChE activity in the hippocampus in the adulthood; which can 207 
explain altered anxiety patterns. Future studies are needed to establish which periods 208 
are BPA-susceptible, levels needed, the effects induced and the mechanisms 209 
underlying it.    210 
There were some limitations to this study. A single first urine sample may not predict 211 
the real BPA exposure, due to its short biological half-life and to temporal variability of 212 
BPA urinary concentration (1).  In fact, the median concentration of our sample (0.36 213 
ng/mL unadjusted and 0.36 ng/mL creatinine adjusted) is lower than other reports (2.2 214 
ng/ml unadjusted and 1.63 ng/mL creatinine adjusted). Another point that needs to be 215 
further evaluated is the possible routes of BPA exposure, for example diet and dental 216 
products, which can explain the extreme BPA concentrations of some samples (namely 217 
3 values very high and two inferior to the LOD). Our sample size was very modest, 218 
which reduced the statistical power and also impended to conclude about a gender-219 
dependent association. Other point that took our attention was that our sample 220 
presented higher levels of perceived stress and negative affects, compared to the 221 
general population with the same age (26, 28). Extend the study to other demographic 222 
groups may overcome this issue.    223 
In summary, our findings suggest possible effects of BPA on psychometric parameters 224 
on young adults. Additional studies are necessary to evaluate the action on behavior of 225 
this endocrine disruptor, present ubiquitous in our daily life. 226 
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Table 1 - Social-demographical characteristics of the individuals included in the study 
Demographic Variables Total (N=24) Female (N=12) Male (N=12) 
Age (years): M (SD) 23.00 (0.30) 22.92 (0.29) 23.08 (0.30) 
Civil state (single) 100.00 100.00 100.00 
Education (Higher education,%) 100.00 100.00 100.00 
Socioeconomic status       
Lower middle class (%) 41.70 41.70 41.70 
Upper middle class (%) 58.30 58.30 58.30 
Chronic Diseases (%) 0.00 0.00 0.00 
Psychiatric disorders 0.00 0.00 0.00 
Chronic Medication (%) 0.00 0.00 0.00 
Smoking (%)       
Never 45.80 66.70 25.00 
Ocasional 37.50 25.00 50.00 
Less than 10/day 4.20 0.00 8.30 
11-20/day 12.50 8.31 16.70 
Alcohol Habits (%)       
Never 0.00 0.00 0.00 
1 /month 16.70 25.00 8.30 
2-4/month 66.70 75.00 58.30 
2-3/week 16.70 0.00 33.30 
M- Mean; SD – Standard Deviation;  
 
 
 
 
Table 2- First morning urine BPA unadjusted and creatinine adjusted concentrations 
Urinary Values All (N:24) Female (N:12) Male (N:12) p-value 
Bisphenol Unadjasted (ug/L)  
(M, SD) 0.37 (0.23) 0.35 (0.21) 0.39 (0.26) 0.688 
Bisphenol Creatinine Adjusted (ug/L) 
(M,SD) 0.34 (0.33) 0.39 (0.30) 0.28 (0.36) 0.462 
a Creatinine-adjusted urinary BPA concentrations were calculated by dividing urinary 
BPA concentrations by urinary creatinine concentrations, to control for urine dilution.  
M – Mean; SD- Standard Deviation; p-value (<0,05). 
 
 
 
 
 
 
 
Table 3 – Distribution of the PANAS, HADS and PSS score outcomes in the cohort of 
24 individuals  
Scales 
Mean (minimum and maximum) All (N:24) Female (N:12) Male (N:12) p-value 
PANAS         
Positive 33.38 (25, 45) 32.75 (25, 45) 34.00 (29, 40) 0.567 
Negative 22.04 (11, 34) 22.17 (11,34) 21.92 (12, 32) 0.932 
HADS         
Anxiety 7.71 (3, 15) 7.50 (3,15) 7.92 (3, 13) 0.771 
Depression 3.50 (0, 9) 3.50 (1,9) 3.50 (0, 8) 1.00 
PSS 22.58 (10, 34) 22.08 (10,27) 23.08 (15, 34) 0.714 
PANAS - Positive and negative affect; HADS - Hospital Anxiety and Depression Scale; 
PSS - Perceived Stress Scale. p- value (< 0,05) 
 
 
 
 
Table 4 – Pearson Correlation between the PANAS, HADS and PSS 
  
PANAS  
positive 
PANAS 
negative 
HADS 
anxiety 
HADS 
depression 
PSS 
 
PANAS 
positive 
Pearson 
correlation 1  -0.36  -0.39  -0.45 0.24 
p-value   0.077 0.62 0.28 0.257 
PANAS 
negative 
Pearson 
correlation  -0.39 1 0.73 0.71  -0.53 
p-value 0.077   0.000 0.000 0.008 
HADS 
anxiety 
Pearson 
correlation  -0.39 0.73 1 0.61  -0.66 
p-value 0.062 0.000   0.002 0.000 
HADS 
 
Depression 
Pearson 
correlation  -0.45 0.713 0.61 1  -0.51 
p-value 0.028 0.000 0.002   0.011 
PSS 
 
Pearson 
correlation 0.24  -0.53  -0.66  -0.51 1 
p-value 0.257 0.008 0.000 0.011   
N=24 
p-value < 0,05 
HADS - Hospital Anxiety and Depression Scale; PANAS - Positive and negative affect 
Scale; PSS - Perceived Stress Scale 
 
 
 
 
 
 
 
 
 
 
 
Table 5 – Adjusted association between urinary bisphenol A concentration and the 
scores from the PANAS, HADS and PSS.  
Scales (N=24) Beta unstandardized 95 % CI p - value R square 
PANAS         
positive  0.16   -7.41,  7.74 0.964 0.09 
negative -9.54  -18.50, -0.58 0.038 0.29 
HADS         
anxiety  -3.65  -8.02, 0.89 0.108 0.24 
depression  -2.41 -6.12, 1.33 0.193 0.11 
PSS  4.12 -5.10, 13.33 0.360 0.14 
The analyses were adjusted for socioeconomic status, smoking, alcohol habits and 
gender (relatively to gender, beta-undstandardized for each scale between -0.15 and 
0.96) 
Creatinine-standardized values were used for urinary bisphenol A concentration.  
p-value < 0,05 
CI - confidence inter; HADS - Hospital Anxiety and Depression Scale; PANAS - 
Positive and negative affect Scale; PSS - Perceived Stress Scale. 
 
 
  
 
Table 6 – Comparison of the adjusted association between urinary bisphenol A concentration and the scores from the PANAS, HADS and PSS 
in females and in males.  
 
Female (N=12) Male (N=12) 
Scales 
Beta 
unstardardized 95 % CI 
p - 
value 
R 
square 
Beta 
unstardardized 95 % CI 
p - 
value 
R 
square 
PANAS                 
positive 8.91  -9.23, 27.06 0.283 0.25  -6.73   -17.43, 3.97 0.181 0.34 
negative -12.06  -28.11, 3.98 0.119 0.44 -8.69 -29.78, 12.41 0.362 0.22 
HADS                 
 anxiety  -7.44  -.18.29, 3.40 0.148 0.33  -4.05  -11.60, 9.43 0.245 0.35 
 depression  -4.25  -10.85, 2.36 0.172 0.39 -0.94  -8.52, 6.63 0.777 0.23 
PSS 7.11  -12.30, 26.53 0.415 0.31 2.94  -13.81, 19.70 0.690 0.38 
The analyses were adjusted for socioeconomic status, smoking and alcohol habits. Creatinine-standardized values were used for urinary 
bisphenol A concentration. 
p-value < 0,05 
CI - confidence inter; HADS - Hospital Anxiety and Depression Scale; PANAS - Positive and negative affect Scale; PSS - Perceived Stress 
Scale; SE, standard error. 
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INSTRUCTIONS FOR AUTHORS
1. Aims and Scope
The International Journal of Clinical Neurosciences and Mental Health is an open-access 
peer-reviewed journal published trimonthly by ARC Publishing. 
Our goal is to provide high-quality publications in the areas of Psychiatry and Mental Health, 
Neurology, Neurosurgery and Medical Psychology. Expert leaders in these medical areas 
constitute the international editorial board. 
The journal publishes original research articles, review articles, drug reviews, case reports, 
case snippets, viewpoints, letters to the editor, editorials and guest editorials. 
The International Journal of Clinical Neurosciences and Mental Health follows the highest 
scientific standards, such as the CONSORT / STROBE guidelines and the Uniform Requirements 
for Manuscripts Submitted to Biomedical Journals (ICJME).
The journal offers:
• Trusted peer review process
• Fast submission-to-publication time
• Open-access publication without author fees
• Multidisciplinary audience and global exposure
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2. Types of papers
The International Journal of Clinical Neuroscience and Mental Health publishes scientific 
articles in the following categories:
• Original research articles. 
• Reviews.
• Drug reviews.
• Case reports.
• Case snippets.
• Viewpoints.
• Letters to the editor.
• Editorials and guest editorials.
2.1. Original research articles
The International Journal of Clinical Neurosciences and Mental Health welcomes original 
clinical research related with psychiatry, mental health, medical psychology, neurosurgery and 
neurology. 
Reports of randomized clinical trials should follow the CONSORT Guidelines and reports of 
observational studies should comply with STROBE Guidelines. 
Body text of an Original Research Article should have no more than 4000 words (word 
count excludes title page, abstract, acknowledgments, references and tables). A maximum of 6 
illustrations (figures or tables) are allowed. Supplementary online material may be submitted at 
the editor discretion.
2.2. Review articles and Drug Reviews
Review articles on CNS-related drugs, psychiatry, mental health, medical psychology, 
neurosurgery and neurology topics are welcome. Both invited and unsolicited submissions are 
accepted.
Manuscripts should be limited to a maximum of 4,500 words, excluding title page, abstract, 
acknowledgments, references and tables. 
2.3. Case reports and case snippets
Case Reports and Case Snippets should have no more than 750 and 500 words, respectively 
(word count excludes references); one figure or table can be included. 
Only highly meaningful Case Reports are accepted, including major educational content or 
major clinical findings. Case Snippets should describe a diagnosis or therapeutic challenge.
2.4. Viewpoints
Viewpoints should provide an expert opinion on important topics for medical research or 
practice, with possibility for covering social and policy aspects. This section encourages dialogue 
and debate on relevant issues with expert views based on evidence.
Viewpoints are limited to 1500 words (word count excludes references) and can include one 
figure or table.
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2.5. Letters to the Editor
Letters to the Editor should share views on published articles, any findings insufficient for a 
research article or present ideas of any subject in the scope of the journal.
Letters to the Editor have a maximum of 600 words (including references) and can include 
one figure or table.
2.6. Editorials and Guest Editorials
Authors are invited by the Editor-in-Chief to comment on specific topics and express their 
opinions. Editorials and Guest Editorials have a maximum of 1,000 words and can include one 
figure or table.
3. Manuscript Submission
These instructions advise on how the manuscript should be prepared and submitted. 
Manuscripts that do not comply with the guidelines will not be considered for review.
All manuscripts should be prepared in A4-size or US-letter size, in UK or US English. 
Manuscripts should be submitted in *.doc and *.pdf formats, in the appropriate section of the 
journal website: IJCNMH online submission.
3.1. Cover Letter
A cover letter should be submitted together with the manuscript, in *.doc or *.pdf format, 
addressed to the Editor-in-Chief. 
A template for the cover letter is available for download.
The cover letter should contain statements about originality of your publication, Ethics 
Committee approval and informed consent (if applicable), conflicts of interest and why in your 
opinion your manuscript should be published.
3.2. Manuscript Preparation
The manuscript must be divided in 2 files: the Title page (submitted in *.doc format and *.pdf 
formats) and the Manuscript body (submitted in *.doc and *.pdf formats). 
Title page
This should be submitted as a separate file from your manuscript (to assure anonymity in the 
peer review process) and should include:  
• Article title.
• Authors’ names, titles (e.g. MD, PhD, MSc, etc.) and institutional affiliations.
• Corresponding author: name, mailing address, telephone and fax numbers.
• Keywords (maximum of 10).
• A running head (up to 50 characters).
• Abstract word count (up to 250 words).
• Body text word count. 
• The number of figures and tables.
Instructions for Authors
4
Manuscript body:
The Manuscript body must be anonymous, not containing the names or affiliations of the 
authors. Manuscript body must be structured in the following order: title, abstract, body text, 
acknowledgements, references, tables, and figures captions/legends.
• The text must be formatted as follow:
• Arial fonts, size: 11 points.
• Single line spacing (see paragraph menu). 
• Aligned to the left (not justified). 
Showing continuous line numbers on the left border of the page. For MS Word you can add 
line numbers by going to: Page Layout -> Line Numbers -> select “Continuous”; for OpenOffice:  
Tools -> Line Numbering -> tick “Show numbering”.
Title  
A descriptive and scientifically accurate article title should be provided.
Abstract (250 words maximum)
An abstract should be prepared for Original Research Articles, Review Articles and Drug 
Reviews.
Should be structured and include: background/objective, material and methods, results, and 
conclusions. These sections should be separated by the respective headings. 
If the publication is associated with a registered clinical trial, the trial registration number 
should be referred at the end of the abstract.
Body text
Original research articles
Original research articles should be structured as follows:
Introduction: Should present the background for the investigation and justify its relevancy. 
Claims should be supported by appropriate references. Introduction should end by stating 
the objectives of the study.
Methods: Should allow the reproduction of results and therefore must provide enough 
detail. Appropriate subheadings can be included, if needed.
Results: Should include detailed descriptions of generated data. This section can be 
separated into subsections with concise self-explanatory subheadings.
Discussion and Conclusions: Should be brief but comprehensive and well argued, 
summarise and discuss the main findings, their clinical relevance, the strengths and 
limitations of the study, future perspectives with suggestion of experiments to be addressed 
in the future.
Review articles and Drug Reviews
These types of articles should be organized in sections and subsections.
Acknowledgements
This section should name everyone who has contributed to the work but does not qualify as 
an author. People mentioned in this section must be informed and only upon consent should 
their names be included along with their contributions. Financial support (with grant number, if 
applicable) should also be stated here.
Any conflict of interests should be declared. If authors have no declaration it should be 
written: “The authors declare no conflict of interests”.
References
References citation in the text should be numbered sequentially along the text, within 
brackets. 
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The use of a reference management tool (such as Endnote or Reference Manager) is 
recommended. References must be formatted in Vancouver style. 
Only published or accepted for publication material can be referenced. Personal 
communications can be included in the text but not in the references list. 
Tables
Tables should be smaller than a page, without picture elements or text boxes. Tables should 
have a concise but descriptive title and should be numbered in Arabic numerals. Table footnotes 
should explain any abbreviations or symbols that should be indicated by superscript lower-case 
letters on the body table.
Figures
Figures should have a concise but descriptive title and should be numbered in Arabic 
numerals. If the article is accepted for publication, the authors may be asked to submit higher 
resolution figures. Copyright pictures shall not be published unless you submit a written consent 
from the copyright holder to allow publishing.
Each figure file shall not be larger than 30MB. 
Figures should be tested and printed on a personal printer prior submission. The printed 
image, resized to the intended dimensions, is almost a replication of how the picture will look 
online. It shall be clearly perceived, non-pixelated nor grainy. Only flattened versions of layered 
images are allowed. Each figure can only have a 2-point white space border, thus cropping is 
strongly advised. For text within figures, Arial fonts between 8 to 11 points should be used and 
must be readable. When symbols are used, the font information should be embedded.
Photographs should be submitted as *.tif or *.eps at high-resolution (300 dpi or more). 
Graphics should be submitted in *.eps format. MS Office graphics are also acceptable.
All figures, tables and graphics should have white background and not transparent.
Lines, rules and strokes should be between 0.5-1.5 points for reproducibility purposes.
3.3. Supporting Information
Code of Experimental Practice and Ethics
The minimal ethics requirements are those recommended by the Code of Ethics of the World 
Medical Association (Declaration of Helsinki). Authors should provide information regarding 
ethics on research participants, patient informed consent, data privacy as well as competing 
interests. If the authors have submitted a related manuscript elsewhere should disclose this 
information prior submission. 
Nomenclature
All units should be in International System (SI). Drugs should be designated by their 
International Non-Proprietary Name (INN).
3.4. Submission Checklist
Please ensure you have addressed the following issues prior submission:
• Details for competing interests.
•  Details for financial disclosure.
•  Details for authors contribution.
•  Participants informed consent statement.
•  Contributor copyright authorization of figures included in the manuscript, not produced 
by the authors and subjected to copyright.
•  Authorship, affiliations and email addresses are correct.
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•  Cover letter addressed to the Editor-in-Chief.
•  Identification of potential reviewers and their email addresses (to be introduced at the 
online submission platform).
•  Manuscript, figure and tables comply with the author guidelines, including the correct 
format, SI units and standard nomenclature.
•  Separated files for Title page (*.doc and *.pdf) and Manuscript body (*.doc and *.pdf)—4 
in total.
•  Manuscript body does not contain the names or affiliations of the authors.
If you have any questions, please contact ijcnmh@arc-publishing.org
4. Overview of the Editorial Process
The International Journal of Clinical Neurosciences and Mental Health aims to provide an 
efficient and constructive view of the manuscripts submitted to achieve a high quality level of 
publications. The editorial board is constituted by expert leaders in several areas of medicine 
particularly in Clinical Neuroscience and Mental Health.  
Once submitted, the manuscript is assigned to an editor which evaluates and decides whether 
the manuscript is accepted for peer-review. At this initial phase, the editor evaluates if the 
manuscript fulfils the scope of the journal according to the content and minimum quality 
standards.  For peer-review, one or two additional expert field editors will comment on the 
manuscript and decide on whether it is accepted for publishing with minor corrections or not 
accepted for publishing. The editor may ask authors to resubmit after major revision. Decision 
is based on technical and scientific merits of the work. Reviewers can be asked to be disclosed 
or stay anonymous. Authors can exclude specific editors or reviewers from the process, upon 
submission, a rational should be provided.
Upon evaluation, an email is sent to the corresponding author with the decision. If accepted, 
the manuscript enters the production process. It takes approximately 6-7 weeks for the 
manuscript to be published.
4.1. Appeal Process
The editors will respond to appeals from authors which manuscripts were rejected. Their 
interests should be sent to the Editor. 
Two directions can be followed: 
• If the Editor does not accept the appeal, further right to appeal is denied.
• If the Editor accepts the appeal, a further review will be asked. After the new review, the 
editor can reject or accept the appeal. If rejected, nothing else can be done, if accepted the 
author is able to resubmit the manuscript.
The reasons for not accepting a manuscript for consideration can be:
•  The manuscript does not follow the scope of the journal.
•  The manuscript has potential interest but there are methodological concerns after peer-re-
view or editorial examination.
Positive	  and	  Negative	  Affect	  Schedule	  -­‐	  PANAS	  	  
	  
Esta	  escala	  consiste	  num	  conjunto	  de	  palavras	  que	  descrevem	  diferentes	  sentimentos	  e	  
emoções.	  Leia	  cada	  palavra	  e	  marque	  a	  resposta	  adequada	  no	  espaço	  anterior	  à	  palavra.	  
Indique	  em	  que	  medida	  sentiu	  cada	  uma	  das	  emoções	  durante	  a	  última	  semana:	  
	  
1-­‐	  Nada	  ou	  muito	  Ligeiramente.	  	  
2	  -­‐	  Um	  Pouco	  	  
3	  -­‐	  Moderadamente	  	  
4	  -­‐	  Bastante	  	  
5	  -­‐	  Extremamente 
 
 
	   	   ___	  Interessado	  	   	   	  
	   	   ___	  Orgulhoso	  
	   	   ___	  Perturbado	  	  
	   	   ___	  Irritado	  
	   	   ___	  Excitado	  	  
	   	   ___	  Encantado	  
	   	   ___	  Atormentado	  	  
	   	   ___	  Remorsos	  
	   	   ___	  Agradavelmente	  surpeendido	  	  
	   	   ___	  Inspirado	  
	   	   ___	  Culpado	  	  
	   	   ___	  Nervoso	  
	   	   ___	  Assustado	  	  
	   	   ___	  Determinado	  
	   	   ___	  Caloroso	  	  
	   	   ___	  Trémulo	  
	   	   ___	  Repulsa	  	  
	   	   ___	  Activo	  
	   	   ___	  Entusiasmado	  	  
	   	   ___	  Amedrontado 
ESCALA	  DE	  ANSIEDADE	  E	  DEPRESSÃO	  HOSPITALAR	  –	  HADS	  
	  
Este	   questionário	   foi	   construído	   para	   ajudar	   a	   saber	   como	   se	   sente.	   Pedimos-­‐lhe	   que	   leia	   cada	  
uma	  das	  perguntas	  e	  faça	  uma	  cruz	  (X)	  no	  espaço	  anterior	  à	  resposta	  que	  melhor	  descreve	  a	  forma	  
como	  se	  tem	  sentido	  na	  última	  semana.	  Não	  demore	  muito	  tempo	  a	  pensar	  nas	  respostas.	  A	  sua	  
reacção	   imediata	  a	  cada	  questão	  será	  provavelmente	  mais	  correcta	  do	  que	  uma	  resposta	  muito	  
ponderada.	  
Por	  favor,	  faça	  apenas	  uma	  cruz	  em	  cada	  pergunta.	  
	  
1.	  Sinto-­‐me	  tenso/a	  ou	  nervoso/a:	  
(	  )	  Quase	  sempre	  
(	  )	  Muitas	  vezes	  
(	  )	  Por	  vezes	  
(	  )	  Nunca	  
	  
2.	  Ainda	  sinto	  prazer	  nas	  coisas	  de	  que	  costumava	  gostar:	  
(	  )	  Tanto	  como	  antes	  
(	  )Não	  tanto	  agora	  
(	  )Só	  um	  pouco	  
(	  )	  Quase	  nada	  
	  
3.	  Tenho	  uma	  sensação	  de	  medo,	  como	  se	  algo	  terrível	  estivesse	  para	  acontecer:	  
(	  )	  Sim	  e	  muito	  forte	  
(	  )	  Sim,	  mas	  não	  muito	  forte	  
(	  )	  Um	  pouco,	  mas	  não	  me	  aflige	  
(	  )	  De	  modo	  algum	  
	  
4.	  Sou	  capaz	  de	  rir	  e	  ver	  o	  lado	  divertido	  das	  coisas:	  
(	  )	  Tanto	  como	  antes	  
(	  )Não	  tanto	  como	  antes	  
(	  )	  Muito	  menos	  agora	  
(	  )	  Nunca	  
	  
5.	  Tenho	  a	  cabec¸a	  cheia	  de	  preocupaçõess:	  
(	  )	  A	  maior	  parte	  do	  tempo	  
(	  )	  Muitas	  vezes	  
(	  )	  Por	  vezes	  
(	  )	  Quase	  nunca	  
	  
6.	  Sinto-­‐me	  animado/a:	  
(	  )	  Nunca	  
(	  )	  Poucas	  vezes	  
(	  )	  De	  vez	  em	  quando	  
(	  )	  Quase	  sempre	  
	  
7.	  Sou	  capaz	  de	  estar	  descontraidamente	  sentado/a	  e	  sentir-­‐me	  relaxado/a:	  
(	  )	  Quase	  sempre	  
(	  )	  Muitas	  vezes	  
(	  )	  Por	  vezes	  
(	  )	  Nunca	  
	  
8.	  Sinto-­‐me	  mais	  lento/a,	  como	  se	  fizesse	  as	  coisas	  mais	  devagar:	  
(	  )	  Quase	  sempre	  
(	  )	  Muitas	  vezes	  
(	  )	  Por	  vezes	  
(	  )	  Nunca	  
	  
9.	  Fico	  de	  tal	  forma	  apreensivo/a	  (com	  medo),	  que	  até	  sinto	  um	  aperto	  no	  estômago:	  
(	  )	  Nunca	  
(	  )	  Por	  vezes	  
(	  )	  Muitas	  vezes	  
(	  )	  Quase	  sempre	  
	  
	  
10.	  Perdi	  o	  interesse	  em	  cuidar	  do	  meu	  aspecto	  físico:	  
(	  )	  Completamente	  
(	  )Não	  dou	  a	  atenção	  que	  devia	  
(	  )	  Talvez	  cuide	  menos	  que	  antes	  
(	  )	  Tenho	  o	  mesmo	  interesse	  de	  sempre	  
	  
11.	  Sinto-­‐me	  de	  tal	  forma	  inquieto/a	  que	  não	  consigo	  estar	  parado/a:	  
(	  )	  Muito	  
(	  )	  Bastante	  
(	  )Não	  muito	  
(	  )	  Nada	  
	  
12.	  Penso	  com	  prazer	  nas	  coisas	  que	  podem	  acontecer	  no	  futuro:	  
(	  )	  Tanto	  como	  antes	  
(	  )Não	  tanto	  como	  antes	  
(	  )	  Bastante	  menos	  agora	  
(	  )	  Quase	  nunca	  
	  
13.	  De	  repente,	  tenho	  sensações	  de	  pânico:	  
(	  )	  Muitas	  vezes	  
(	  )	  Bastantes	  vezes	  
(	  )	  Por	  vezes	  
(	  )	  Nunca	  
	  
14.	  Sou	  capaz	  de	  apreciar	  um	  bom	  livro	  ou	  um	  programa	  de	  rádio	  ou	  televisão:	  
(	  )	  Muitas	  vezes	  
(	  )	  De	  vez	  em	  quando	  
(	  )	  Poucas	  vezes	  
(	  )	  Quase	  nunca	  
	  
	  
	  
MUITO	  OBRIGADO	  PELA	  SUA	  COLABORAÇÃO. 
Perceived	  Stress	  Scale	  
	  
Para	  cada	  questão,	  pedimos	  que	  indique	  com	  que	  frequência	  se	  sentiu	  ou	  pensou	  de	  determinada	  
maneira,	   durante	   o	   ultimo	   mes.	   Apesar	   de	   algumas	   perguntas	   serem	   parecidas,	   existem	  
diferenças	   entre	   elas	   e	   deve	   responder	   a	   cada	   uma	   como	   perguntas	   separadas.	   Responda	   de	  
forma	  rápida	  e	  espontânea.	  Para	  cada	  questão,	  escolha	  a	  alternativa	  que	  melhor	  se	  ajusta	  à	  sua	  
situação.	  
	  
0	  -­‐	  Nunca.	  1	  -­‐	  Quase	  nunca.	  2	  -­‐	  Algumas	  vezes.	  3	  -­‐	  Frequentemente.	  4	  -­‐	  Muito	  frequentemente.	  
	  
1.	  No	  último	  mês,	  com	  que	  frequência	  esteve	  preocupado(a)	  por	  causa	  de	  alguma	  coisa	  
que	  aconteceu	  inesperadamente?	  
2.	  No	  último	  mês,	  com	  que	  frequência	  se	  sentiu	  incapaz	  de	  controlar	  as	  coisas	  importantes	  
da	  sua	  vida?	  
3.	  No	  último	  mês,	  com	  que	  frequência	  se	  sentiu	  nervoso(a)	  e	  em	  stresse?	  
4.	  No	  último	  mês,	  com	  que	  frequência	  sentiu	  confiança	  na	  sua	  capacidade	  para	  enfrentar	  
os	  seus	  problemas	  pessoais?	  
5.	  No	  último	  mês,	  com	  que	  frequência	  sentiu	  que	  as	  coisas	  estavam	  a	  correr	  à	  sua	  
maneira?	  
6.	  No	  último	  mês,	  com	  que	  frequência	  sentiu	  que	  não	  aguentava	  com	  as	  coisas	  todas	  
que	  tinha	  para	  fazer?	  
7.	  No	  último	  mês,	  com	  que	  frequência	  foi	  capaz	  de	  controlar	  as	  suas	  irritações?	  
8.	  No	  último	  mês,	  com	  que	  frequência	  sentiu	  ter	  tudo	  sob	  controlo?	  
9.	  No	  último	  mês,	  com	  que	  frequência	  se	  sentiu	  furioso(a)	  por	  coisas	  que	  ultrapassaram	  
o	  seu	  controlo?	  
10.	  No	  último	  mês,	  com	  que	  frequência	  sentiu	  que	  as	  dificuldades	  se	  estavam	  a	  acumular	  
tanto	  que	  não	  as	  conseguia	  ultrapassar? 
 



